Bivalirudin Compared to Heparin as the Primary Anticoagulant in Pediatric Berlin Heart Recipients. Issue 5 (20th March 2023)

• Record Type: Journal Article
• Authors: Freniere, Victoria; Salerno, David M.; Corbo, Heather; Law, Sabrina; McAllister, Jennie; Neunert, Cindy; Chen, Justin K.
• Is Part Of: ASAIO journal. Volume 69:Issue 5(2023)
• Page Start: e205
• Page End: e211
• Publication Date: 2023-03-20
• Subjects: pediatric -- ventricular assist device -- bivalirudin -- heparin -- anticoagulation; Artificial organs -- Periodicals; 617
• DOI: 10.1097/MAT.0000000000001921
• Languages: English
• ISSNs: 1058-2916

Abstract

Abstract : Bivalirudin has been used in increasing frequency as an alternative to unfractionated heparin (UFH) in pediatric recipients of Berlin Heart EXCOR ventricular assist devices (VAD). This single-center, retrospective review characterizes anticoagulant trends and outcomes in pediatric Berlin Heart VAD recipients implanted between September 1, 2013, and August 31, 2021, anticoagulated with either bivalirudin or UFH. Thirty-one patients were included; 65% who received bivalirudin and 35% who received UFH. The median age was 2.9 years, included 64.5% females, with 61.3% of patients diagnosed with dilated cardiomyopathy and 25.8% of patients with congenital heart disease. Therapeutic anticoagulation was achieved sooner in the bivalirudin group compared to UFH via anti-Xa monitoring (median 5.7 and 69.5 hours, respectively, p < 0.001). Bivalirudin had a greater number of therapeutic values comparatively to UFH (52% and 24%, respectively; p < 0.001) and a superior number of hours in the therapeutic range (67% and 32%, respectively; p < 0.001). Secondary outcomes were similar among the two groups, apart from greater chest tube output (UFH), more frequent events of elevated plasma-free hemoglobin (bivalirudin), and more frequent elevated inflammatory markers postimplant (bivalirudin). Prevalence of pump replacements secondary to significant clot burden and prevalence of stroke was comparable. In this patient cohort, bivalirudin demonstrated greater anticoagulation stability comparatively to UFH. Multicenter collaboration would be necessary to identify whether this further translates into improved patient outcomes.